Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- iPark Institute Takes Over Shonan iPark Operations from Takeda to Boost Neutrality, Collaborations
April 14, 2023
- Sawai Moved Ahead with WPP Rate Hikes for Generics amid Tough Biz Environment
April 14, 2023
- Chugai, TWOCELLS End Knee Chondrogenesis Cell Therapy Deal
April 14, 2023
- Kaken Aborts ART-648 Program, Incurring 1.5 Billion Yen Impairment Loss
April 14, 2023
- AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
- Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
April 13, 2023
- PET Imaging Agent Vizamyl Filed for Additional Use for AD Modifying Drug
April 13, 2023
- Alexion Japan Recalling Ultomiris IV 300 mg/3 mL
April 13, 2023
- Japan Lacks Talent, Ecosystem to Incubate Drug Seeds: Chugai Chair
April 13, 2023
- Astellas, Kyoto University’s CiRA Extend iPS Cell Pact
April 13, 2023
- Astellas Incurs 58 Billion Yen Impairment Loss on Sluggish Evrenzo, Other Factors
April 12, 2023
- Sumitomo’s SaMD for Depression Gets Priority Review; Clinical Trial Launch Eyed within 3 Years
April 12, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Shionogi Seeks EUA for Xocova in Taiwan
April 12, 2023
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Wakamoto to Halt Shipments of MaQaid on Quality Issues
April 11, 2023
- Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
April 11, 2023
- MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
April 11, 2023
- Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
April 11, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…